Prevention and Alcohol (R61/R33 Clinical Trials Optional)
🏛 National Institutes of Health (HHS-NIH11)
✓ Free, no account · Source: Grants.gov · Last verified Oct 18, 2026
Can you apply?
This grant is for researchers developing and testing HIV prevention interventions that address alcohol use and comorbidities. Eligible applicants include research institutions, universities, and nonprofit organizations with the capacity to conduct NIH-funded research. The R61 phase supports development and pilot testing of novel interventions. The R33 phase expands testing to effectiveness and implementation studies. Awards are made nationally to applicants meeting NIH institutional requirements.
Applicants must have institutional NIH infrastructure including IRB and compliance offices. Research may occur in diverse populations and settings. Both basic innovation and implementation science approaches are supported.
The grant uses a two-phase structure with milestone-driven progression from R61 to R33 based on achieving specific research objectives.
Not the right fit? Find grants for your organization in 5 questions →
Key dates
- Oct 1, 2026 Applications open
- Sep 7, 2027 Application deadline in 323 days
- Mar 1, 2028 Award announced
- Apr 1, 2028 Project start
Program description
This Notice of Funding Opportunity (NOFO) uses a R61/R33 Phased Innovation Award to support milestone-driven research that advances innovative HIV prevention interventions from development and feasibility testing to larger-scale efficacy, effectiveness, implementation, and dissemination studies. The R61 phase will support the development, refinement, adaptation, and pilot testing of novel or enhanced HIV prevention and treatment strategies, including studies designed to address key scientific, operational, or implementation questions necessary to establish feasibility and readiness for larger-scale evaluation. Projects may generate evidence needed to optimize intervention design, delivery, and implementation in diverse populations and settings. The R33 phase will support expanded testing of interventions and implementation strategies that have successfully met R61 milestones. Studies may evaluate effectiveness, implementation, scalability, sustainability, clinical management, or delivery of HIV prevention interventions that include integrated approaches addressing alcohol use and related comorbidities.
Who can apply
Eligible applicants
How to apply
Application links
Key dates & requirements
Required documents
- R&R Application (SF-424 equivalent)
- Project Narrative
- Research Plan with R61 and R33 components
- Budget and Budget Justification
- Biographical Sketches (key personnel)
- Institutional supporting documents (IRB approval, compliance verification)
Program contact
- 👤 HIV/AIDS and Alcohol Research Program
- 📧 NIAAA-HIV@nih.gov
- 📞 301-402-0332
Funding track record
Recent awards under CFDA 93.273 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$131,608,116
-
$34,675,742
-
$34,469,501
-
$33,261,336
-
$33,077,338
-
$32,897,567
-
$30,394,602
-
$30,371,564
-
$29,223,384
-
$29,195,978
Top States by Funding
- CA 16 awards $250.9M
- NY 3 awards $172.8M
- OR 7 awards $96.9M
- NC 4 awards $67.1M
- IN 3 awards $61.9M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.273). How funding has trended year over year.
| 2024 | $430,377,419 | |
| 2025 | $429,906,735 | |
| 2026 est. | $12,401,560 |
FAQ
What is the difference between R61 and R33 phases?
The R61 phase funds development, refinement, and pilot testing of novel HIV prevention interventions. The R33 phase expands testing for effectiveness and implementation after meeting R61 milestones.
Can I apply directly to the R33 phase?
No. Applications must start with the R61 phase. R33 funding is available only after successful R61 completion and milestone achievement.
What types of research are supported?
Development and testing of HIV prevention strategies that integrate alcohol use interventions, implementation science, and studies in diverse populations and settings.
What is the award timeline?
The deadline is fixed in September 2027. NIH typically funds up to 5 years total (R61 and R33 combined), but timeline varies by project needs.
What costs can be included in the budget?
Personnel, equipment, research activities, and indirect costs are typically allowable. Consult the full NOFO for detailed budget guidelines.
💡 Tips for applicants
- Clearly articulate specific, measurable milestones for transitioning from R61 to R33. Reviewers must see realistic, achievable targets.
- Address how your intervention addresses alcohol use as an integrated component, not a secondary element. This is central to the program.
- Demonstrate feasibility through preliminary data or pilot work. R61 reviewers want evidence that your approach is viable.
- Explain how your work supports implementation or scalability in real-world settings. Pilot testing alone is insufficient.
- Include diverse populations and settings in your study design from the start. This is a key program priority.
⚠️ Common mistakes
Weak or vague milestones that don't clearly signal readiness for R33 expansion. Treating alcohol use as an afterthought rather than an integrated intervention component. Proposing purely theoretical research without preliminary feasibility data or pilot evidence.
Similar grants
- OPEN Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances (R34 Clinical Trial Required) — National Institutes of Health
- CLOSED Pilot and Feasibility Studies in Preparation for Substance Use and HIV Prevention Intervention and Services Research Trials (R34 Clinical Trial Optional) — National Institutes of Health
- OPEN Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional) — National Institutes of Health
- OPEN High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional) — National Institutes of Health
- OPEN High Priority HIV and Substance Use Research (R01 Clinical Trial Optional) — National Institutes of Health